Please try another search
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Christian Trepo | - | - | Member of Scientific Advisory Board |
Christoph Hubert Huber | 79 | - | Member of Scientific Advisory Board |
Luc Teyton | - | - | Member of Scientific Advisory Board |
Lawrence R. Stanberry | - | - | Member of Scientific Advisory Board |
Ian McGowan | - | 2018 | Chairman of Scientific Advisory Board |
June H. Lee | 58 | 2023 | Independent Director |
Troy A. Ignelzi | 55 | 2023 | Independent Director |
Corinna Zur Bonsen-Thomas | - | 2017 | Independent Non-Executive Director |
Carol L. Brosgart | 71 | 2018 | Independent Non-Executive Director |
Kinam Hong | - | 2019 | Non-Executive Director |
Jurgen Rockstroh | - | 2018 | Member of Scientific Advisory Board |
Philippe Pouletty | 66 | 2013 | Founder & Director |
Camilla Soenderby | 52 | 2024 | Independent Director |
Marc M. P. de Garidel | 66 | 2023 | CEO & Interim Chair of Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review